首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1542907

全球輸血診斷市場 - 2024-2031

Global Transfusion Diagnostics Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

輸血診斷市場規模

全球輸血診斷市場在2023年達到24.9億美元，預計2031年將達到38.4億美元，2024-2031年預測期間複合年成長率為5.7%。

輸血診斷市場動態

由於血癌、嚴重傷害和事故的發生率不斷上升，對這些診斷產品的需求不斷增加。手術數量的增加、研發支出的增加以及新產品推出的成長預計將推動市場成長。

不斷增加的新產品推出以及不斷增加的嚴重傷害和事故案件將推動市場成長。

全球輸血診斷市場主要是由醫療保健產業對診斷產品的需求所推動的，這是由於慢性疾病不斷增加，包括血癌、貧血、鐮狀細胞性貧血、腎臟疾病和輸血傳染感染等嚴重感染。事故、創傷和痛苦手術數量的增加推動了市場的成長。例如，2022 年 8 月，QuidelOrtho Corporation 宣佈為其子公司體外診斷服務提供者 Ortho Clinical 開發的 Ortho 工作站獲得 AABB「符合標準」指定品質印章。該工作站是一种血液檢測系統，具有二合一功能，結合了培養箱和離心機。

各種資金、新穎的技術進步以及最新創新產品的推出數量都在增加，導致對這些輸血診斷的高需求。例如，2022年7月，羅氏推出了Elecsys HCV Duo免疫測定法，這是第一個允許透過單一人體樣本獨立檢測丙型肝炎病毒抗體和抗原狀態的免疫測定法。此測試可以在早期階段檢測出感染，並且可以在患者的恢復階段或出現慢性感染症狀時使用。

與輸血診斷相關的高成本將阻礙市場的成長。

然而，用於輸血診斷的有品質保證的試劑盒和儀器的高比例是限制成長的主要因素。由於缺乏經驗豐富的專業人員，因此很難操作自動化儀器並提供準確的結果。

COVID-19 影響分析

疫情對全球金融預期、營運和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健產業。由於新冠疫情，所有捐血活動都被取消，輸血診斷市場遭受了巨大損失。由於新冠病毒的傳播和輸血傳染，人們拒絕接受輸血。但現在，市場參與者正在改變他們的長期和短期成長策略，利用研究市場並創造尖端產品來對抗這場流行病。全球正在發生各種舉措、合作和合併，促進了市場的成長。例如，2022年8月，體外診斷創新技術提供者QuidelOrtho Corp宣布加入血液與生物治療促進協會成立的聯盟“聯盟”，旨在加強血液供應。

輸血診斷市場區隔分析

疾病篩檢領域預計在預測期內（2024-2031）將以最快的複合年成長率成長

疾病篩檢領域是全球輸血診斷市場中最大的市場佔有者。所有捐贈的血液都經過篩檢，以獲取血液中不存在任何感染的證據，然後再將血液及其成分用於臨床，稱為疾病篩檢。引入針對病毒特異性抗原和抗體的血清學檢測對於檢測捐贈血液中的感染非常有用，例如輸血傳播的傳染源，如 TTI、HIV、乙型肝炎病毒和丙型肝炎病毒。最新核酸擴增技術篩檢，有效降低感染風險。

由於全球血癌病例增加，疾病篩檢在市場上佔據主導地位。根據世界衛生組織統計，到2022年，全球每年約有124萬例血癌病例。患有血液相關疾病的人數不斷增加、監管部門的批准以及技術進步或研究/臨床試驗的不斷發展推動了市場的成長。例如，2022 年 6 月，血漿衍生療法和創新診斷解決方案開發商 Grifols 宣布 Procleix Plasmodium Assay 獲得 CE 標誌，這是第一個專為瘧疾相關患者捐血者設計的自動核酸檢測系統。

輸血診斷市場地理佔有率

北美地區佔據全球輸血診斷市場最大的市場佔有率。

北美在全球輸血診斷市場中佔據主導地位，這主要是由於全球環境不斷變化、醫療基礎設施完善以及對研發活動的投資增加，導致血癌、貧血、血友病、腎臟病等慢性疾病的患病率不斷上升。此外，其廣泛的患者群體也促進了其佔有率的成長。根據世界衛生組織預測，到2022年，全球將有超過200萬人患有貧血症，影響全球約25%的人口。

此外，產品發布數量的增加也是市場成長的原因。其他因素，例如國內生產毛額在醫療保健方面的高支出，刺激了市場的成長。該地區正在發生許多關鍵的發展、技術進步、合作和協議。例如，2022 年 9 月，血漿藥品製造商 Grifols 宣布與加拿大國家血液管理局 Canadian Blood Services 達成協議，以擴大其在基本血漿蛋白療法和免疫球蛋白藥物方面的自給自足。

輸血診斷市場公司及競爭格局

輸血診斷市場與本地和全球公司的競爭非常激烈。 Ortho Clinical Diagnostics、Beckman Coulter、Quotient Limited、Abbott Laboratories、Diagast、Becton、Dickinson & Company、Immucor Inc.、Grifols SA、Bio-Rad Laboratories、F. Hoffmann-La Roche Ltd. 等。主要參與者正在採取各種成長策略，例如產品發布、併購、合作夥伴關係和協作，為市場的成長做出貢獻。例如，2022年5月，Quidel Corporation宣布交易完成，與Ortho Clinical Diagnostics Holdings合併，成立體外診斷產品及服務供應商公司QuidelOrtho Corporation。

骨科臨床診斷：

概述：

Ortho Clinical Diagnostics 是一家提供血型體外診斷設備的公司。它生產自動化和半自動化測試產品以及測試菜單產品。成立於1939年，總部位於美國新澤西州。

產品組合：

Ortho Vision平台：該平台由測試血液相容性的分析儀組成，以確保患者在輸血期間接受正確的血型。正交視覺產品專為大容量實驗室而設計，可進行複雜的免疫血液學測試，包括連續稀釋、識別特定細胞抗體和反射測試。

主要進展：2021 年 9 月，體外診斷公司 Ortho Clinical Diagnostics 宣布推出立即旋轉交叉配血 (ISXM)，該系統將有助於確定受血者和捐贈者之間輸血過程中的不相容性。此血清學檢驗可確定受者血漿和供者紅血球之間 ABO 血型的不相容性。

全球輸血診斷市場報告將提供約 40 多個市場資料表、45 多個圖表和 200（大約）頁數。

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market's growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB "standards compliant" designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient's recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market's growth.

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Transfusion Diagnostics Market Segmentation Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection.

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria.

Transfusion Diagnostics Market Geographical Share

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world's population.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada's national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Transfusion Diagnostics Market Companies and Competitive Landscape

The transfusion diagnostics market is highly competitive with local and global companies' presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States.

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The rising novel product launches
  - 4.1.1.2. Increasing demand for diagnostic transfusion products
- 4.1.2. Restraints:
  - 4.1.2.1. High cost associated with diagnostic transfusion instruments
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces
5.2. Unmet Needs
5.3. Supply chain Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Instruments & Kits*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Reagents
7.4. Others

8. By Transfusion Types

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 8.1.2. Market Attractiveness Index, By Transfusion Types
8.2. Red Blood Cell Transfusion *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Platelet Transfusion
8.4. Plasma Transfusion
8.5. Whole Blood Transfusion

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Disease Screening *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Blood Typing
9.4. Others

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Blood Banks*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Hospitals
10.4. Laboratories
10.5. Plasma Fractionation Facilities
10.6. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch

13. Company Profiles

13.1. Ortho Clinical Diagnostics
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
13.2. Beckman Coulter
13.3. Quotient Limited
13.4. Abbott Laboratories
13.5. Diagast
13.6. Becton, Dickinson & Company
13.7. Immucor Inc.
13.8. Grifols S.A.
13.9. Bio-Rad Laboratories
13.10. F. Hoffmann-La Roche Ltd.(*LIST NOT EXHAUSTIVE)